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ABSTRACT  
 
Several epidemics of blindness due to retinopathy of prematurity (ROP) have been 
described, with the most recent (the third) occurring in middle income countries in Latin 
America and Eastern Europe initially, and more recently in the more advanced economies in 
Asia. In these settings, which are characterized by variation in the quality of neonatal care 
and inadequate coverage of ROP screening and treatment, larger, more mature infants are 
affected as well as extremely preterm infants. In 2010 the annual incidence of blindness and 
visual impairment from ROP globally was estimated to be 32,300, with the lowest incidence 
in sub-Saharan countries. However, ROP is likely to become an increasingly important 
cause of blindness in children in sub-Saharan Africa as neonatal care expands unless 
policies and programmes for control are included at the outset. 
 
INTRODUCTION 
Retinopathy of prematurity as a cause of blindness in children 
Two epidemics of vision impairment and blindness from retinopathy of prematurity (ROP) 
have been described in high income countries (HICs)(Figure 1), starting in the 1940s. In the 
mid-1990s the third epidemic was described, initially in the upper middle income countries 
(MIC) of Latin America and Eastern Europe.1 The epidemic is now affecting countries in East 
and South Asia, following an increase in the provision of care for sick newborns, including 
those born preterm.2-4 The third epidemic has already started in South Africa,5 which like 
many countries in Latin America and Eastern Europe, is an upper MIC. Some of the more 
advanced economies in Africa, such as Ghana, Nigeria and Kenya are beginning to 
establish ROP screening and treatment services as intensive neonatal care starts to expand.  
 
Visual impairment and blindness from ROP was estimated to affect 32,300 infants globally in 
2010, with marked regional variation.6 The incidence varies markedly, with countries falling 
into three groups: those with very low rates of visual loss (<10 affected/100,000 live births); 
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
3 
 
moderate rates (10-<45/100,000) and higher rates (≥45/100,000)7(Figure 2). Most countries 
with very low rates are low income countries in sub-Saharan Africa (excluding southern 
Africa) where neonatal intensive care is generally not in place and preterm infants have very 
high mortality rates. HICs have moderate rates as visual loss due to ROP is largely being 
controlled by high quality neonatal care, and good access to screening and treatment. 
Countries with high rates of vision loss are those where intensive neonatal care has recently 
expanded, but where the quality of care is variable, with inadequate coverage of ROP 
screening and treatment.8-9 
 
Variation in the characteristics of infants with severe ROP 
The predominant risk factor for ROP is prematurity, with an inverse relationship between 
gestational (GA) and the incidence and severity of ROP. Other risk factors are discussed in 
another paper in this issue.10,11 
 
In HICs only extremely low birth weight (BW) infants develop ROP requiring treatment (i.e., 
Type 1 ROP). For example, in the United Kingdom, the median gestational age (GA) of 
infants treated in 2014 was 25 (interquartile range (IQR) 24.3-26.1) weeks, and the median 
BW was 706 (IQR 620-821) g.12 Data from 29 neonatal units in the US are similar: mean GA 
of infants with Type 1 ROP ranged from 24-25 weeks, and the BW ranged from 604-741 g.13 
However, in countries experiencing the 3rd ROP epidemic, the BW and GA of infants with 
Type 1 ROP can be far higher,14 as in Bangladesh (Figure 3). In this eye hospital study, 
infants were either screened in neonatal units nearby or were referred for examination or 
treatment, or for a second opinion from a large number of eye hospitals or neonatal units. 
Over two years 283 babies were treated, most by laser photocoagulation, or had vitreoretinal 
surgery for Stage 4 or 5 ROP. The median GA was 31.4 (range 24-36) weeks and the 
median BW was 1,400 g (range 600-2,500). 20% had a GA of >32 weeks and a BW of 
>1500 g. Similar findings have been reported from a programme in India where technicians 
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visit a large number neonatal units on a weekly basis to screen for ROP using retinal 
imaging (Figure 4).15 
 
These findings have important implications. Firstly, the quality of neonatal care needs to 
improve to reduce the incidence of ROP. Second, ROP programmes in LMICs need to have 
screening criteria which are wide enough to detect the majority of infants developing Type 1 
ROP. There are no universally applicable criteria.16  
 
ROP in South Africa 
ROP screening started in South Africa in the early 1980’s, largely in private neonatal units 
and tertiary academic institutions (Medical Schools) in large cities. Infants were managed 
using HIC guidelines with comparable outcome.17,18,19,20 Many babies born in lower level 
hospitals in rural areas did not survive, but those who did were transferred for tertiary, high 
quality care with a low incidence of ROP. The National Guideline on the Prevention of 
Blindness (2002)21 included ROP screening guidelines, based on those from the UK and 
USA.   
 
In 1997 the White paper on the Transformation of the Public Health System was published to 
improve access to health care for all citizens, which promoted decentralisation of services to 
district level. By 2006 paediatric services were largely decentralised. An unforeseen casualty 
of this policy was an increase in ROP in larger babies, as more mature premature babies 
were referred down to district hospitals which lacked neonatologists or ophthalmologists, and 
primary health care workers did not know about ROP. There were no oxygen blenders and 
all infants were given 100% oxygen. At the same time the survival of preterm infants born at 
secondary level hospitals increased. Both of these factors led to a marked increase in the 
number of babies needing treatment in KwaZulu-Natal province between 2006 and 2011 
(Figure 5), prompting ophthalmologists and neonatologists to collaborate on modifying the 
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screening guidelines. Legal issues following the increase of blindness due to ROP prompted 
the professional societies of neonatology, ophthalmology and vitreoretinal surgeons to draw 
up national prevention, screening and management guidelines for ROP,5 taking account of 
the local setting. The guidelines, which were drawn up by a ROP Working Group comprising 
ophthalmologists and neonatologists, were based on those of the Royal College of 
Ophthalmologists (UK) and the American Academy of Pediatrics. All provinces now have 
services for ROP. 
In South Africa the guidelines stipulate that following babies are screened: GA <32 weeks or 
BW <1500g, and those with a BW 1,500-2,000 g with risk factors, including unblended 
oxygen supplementation. The first screening is at 4-6 weeks chronological age or 31-33 
weeks post-menstrual age (whichever is later) but no later than 37 weeks post-menstrual 
age. 
Since these guidelines have been followed, there has been a significant decline in the 
number of treatable ROP cases at our centre (Figure 5). 
ROP in Kenya 
Screening for ROP began in Kenya 2010 in private institutions, as a response to improved 
neonatal care and higher survival of premature infants. A few of these infants presented with 
stage 4 or 5 ROP, prompting the litigation-conscious private hospitals to initiate screening. 
The first government hospital to implement screening (in 2014) was the Jaramogi Oginga 
Odinga Teaching and Referral Hospital in Kisumu, Western Kenya. The Kenyatta National 
Hospital, the main teaching and referral hospital with a large neonatal unit (120-180 cots), 
started screening in 2015. In a study in two neonatal units in Nairobi, where the screening 
criteria were <32 weeks or ≤1500 g or more mature infants at the discretion of the 
neonatologist, 16.7% of infants developed any ROP.22 In a further study in Nairobi in which 
more mature infants were eligible for screening (≤35 weeks or ≤1,750 g), 41.7% developed 
any ROP and 20.9% developed Type 1 ROP and were treated.23  
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The screening criteria in Kenya are a BW of <1,501 g or a GA of ≤32 weeks. Neonates with 
a BW 1501-2000 g or GA >32-35 weeks are also screened if they have been exposed to 
high or prolonged oxygen supplementation, extended assisted ventilation, sepsis and poor 
postnatal weight gain, on the recommendation of the neonatologist or pediatrician.  
National ROP guidelines were launched on 30th November 2018 at the first annual 
Ophthalmological Society of Kenya Congress in Nairobi. The guidelines were drawn up by a 
multi-disciplinary technical working group which consisted of technical experts 
(neonatologists, pediatricians and paediatric ophthalmologists and vitreoretinal surgeons), 
methodologists and those who would implement the guidelines. Implementers included 
representatives of the College of Ophthalmology of Eastern, Central and Southern Africa 
(COECSA), neonatal nurses and program managers. The process involved adapting existing 
guidelines, considering the availability and access to different interventions. Following 
extensive consultation a consensus was reached regarding each of the recommendations. 
Over 200 copies of the guideline have been distributed to ophthalmologists and presented at 
regional and local conferences.  
Four government hospitals have been selected to pilot implementation of the guidelines, with 
the support of the Ministry of Health. Further dissemination has been planned through 
resident workshops and local/regional conferences for ophthalmologists, paediatricians and 
nurses. 
ROP activities in Kenya are being coordinated by the Retinopathy of Prematurity Working 
Group, which was convened with the support of the Ophthalmic Services Unit of the Ministry 
of Health. COECSA is the lead implementing partner who helps to bring together other local 
partners. 
ROP in Nigeria 
The first study of ROP screening in Nigeria was undertaken in Ibadan in 1995.24 Screening 
was subsequently discontinued because of the low incidence of ROP and high mortality of 
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affected infants. Screening started in Ilorin in 2007, but was discontinued due to logistical 
problems. Screening was undertaken between 2012 and 2014 in other cities, including 
Ibadan, Lagos, Port Harcourt and Benin,24-27 but the services were irregular.   
During a meeting on ROP for the Africa region in 2016 (organized by the International 
Pediatric Ophthalmology and Strabismus Council (IPOSC)), the likelihood of an epidemic of 
ROP blindness in sub-Saharan Africa was raised. Shortly afterwards, three ROP blind 
infants from different parts of Nigeria presented to our ophthalmology department. This 
suggested that changes in neonatal care have resulted in more preterm infants surviving, 
some whom are developing advanced ROP.28 
In 2017 screening became established in three hospitals in Nigeria, and a national advocacy 
exercise was launched to raise awareness amongst neonatologists. This included 
presentations by members of Nigerian Paediatric Ophthalmology and Strabismus Society at 
the annual scientific meeting of the Nigerian Society for Neonatal Medicine. These initiatives 
led to the creation of a joint ophthalmologist - neonatologists/paediatrician social media 
platform to ease communication, and two joint scientific sessions. 
In some parts of the country there are specialists in retina and paediatric ophthalmology, and 
14 hospitals across Nigeria are now doing some ROP screening and treatment. Capacity to 
scale up and deliver ROP services have been strengthened in several ways. Firstly, through 
a partnership between Ilorin and a centre of excellence for ROP in Odissa State, India who 
have facilitated training workshops. Second, IPOSC members have developed two webinars 
on ROP for Africa, and third, ophthalmologists with more experience in ROP are making 
mentoring visits to assist centres who have recently started ROP programmes.   
An important next step was to develop a national screening protocol to collect data to inform 
national screening criteria for Nigeria. The protocol was agreed through a process of 
consensus and it supersedes the criteria being used previously. It was agreed that between 
September 2018 and August 2019 all infants with a GA of <37 weeks or BW of <2000 g 
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would be screened, with the first examination 3-4 weeks after birth or before discharge, 
whichever is sooner. Screening is taking place in the neonatal unit, and the management 
decision at each examination follows international recommendations. Infants are being 
followed up at 3 months after screening and examined for refractive errors and strabismus. 
After August 2019 the data will be analysed and presented, and decisions made about the 
optimal screening criteria to inform guideline development.   
CONCLUSIONS 
Several countries in sub-Saharan Africa have started services to prevent visual loss from 
ROP. The examples from South Africa, Kenya and Nigeria emphasize the importance of 
committed local leaders, collaboration between ophthalmologists and neonatologists/ 
paediatricians, the need to develop locally relevant, evidence based guidelines, and that 
services can be scaled up with support from professional societies, and input from external 
experts. The active engagement of Ministries of Health and national coordinating bodies are 
also very important for policy change and in scaling up services. 
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Figure 1. Epidemics of blindness due to retinopathy of prematurity. 
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Figure 2. Estimated incidence of vision impairment and blindness from ROP per 100,000 live 
births in 2010.6 
(From Blencowe H, et al. Preterm-associated visual impairment and estimates of retinopathy 
of prematurity at regional and global levels for 2010. Pediatr Res 2013;74 Suppl 1:35-49; 
with permission.) 
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Figure 3. Gestational age and birthweight of babies treated for ROP in an eye hospital in 
Bangladesh in 2016 and 2017. 
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Figure 4. Birthweight and gestational age of infants screened and treated for ROP in a 
telemedicine programme (KIDROP) in India.15  
(Reprinted from Vinekar A, Gilbert C, Dogra M, et al. Indian J Ophthalmol 2014; 62(1): 41-9; 
with permission. The original figure being in colour) 
 
 
  
ACCEPTED MANUSCRIPT
AC
CE
PT
ED
 M
AN
US
CR
IP
T
15 
 
Figure 5.  Number of babies treated for ROP in KwaZulu-Natal between 2008 and 2015 
 
